PLC Systems wins FDA approval for RenalGuard study in US
The FDA also approved PLC’s request to expand their investigation from the 246 patients conditionally approved earlier this year to 406 patients and eliminate the requirement for an
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.